Cite
HARVARD Citation
Steffens, M. et al. (2016). Dosing to rash? – The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. European journal of cancer. pp. 131-139. [Online].